Nurexone Biologic Inc (NRXBF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,989 | -3,524 | -1,678 | -5,043 | -3,497 |
| Depreciation Amortization | 132 | 85 | 43 | 85 | 46 |
| Other Working Capital | 565 | 760 | 336 | -923 | -362 |
| Other Operating Activity | 955 | 626 | 313 | 993 | 660 |
| Operating Cash Flow | $-3,337 | $-2,053 | $-986 | $-4,888 | $-3,153 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -46 | -34 | -32 | -649 | -603 |
| Other Investing Activity | 0 | 0 | 0 | -9 | -10 |
| Investing Cash Flow | $-46 | $-34 | $-32 | $-658 | $-613 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 675 | 603 | 603 | 3,128 | 4,344 |
| Other Financing Activity | 2,887 | 1,897 | 307 | 2,750 | 1,357 |
| Financing Cash Flow | $3,562 | $2,500 | $910 | $5,878 | $5,701 |
| Exchange Rate Effect | 104 | 115 | -4 | -173 | 47 |
| Beginning Cash Position | 700 | 700 | 700 | 541 | 541 |
| End Cash Position | 983 | 1,228 | 588 | 700 | 2,523 |
| Net Cash Flow | $283 | $528 | $-112 | $159 | $1,982 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,337 | -2,053 | -986 | -4,888 | -3,153 |
| Capital Expenditure | -46 | -34 | -32 | -649 | -603 |
| Free Cash Flow | -3,383 | -2,087 | -1,018 | -5,537 | -3,756 |